2024-01-05 バージニア工科大学(VirginiaTech)
◆バージニア工科大学の研究者は、GLP-1薬に関連する約68,000件のReddit投稿を分析し、ユーザーがアルコールとの関係に変化を報告していることを発見しました。また、肥満患者153人を対象にした遠隔研究でも、これらの薬によるアルコール摂取の減少が確認され、過度な飲酒の可能性も低下しています。
◆これらの結果は、GLP-1アゴニストがアルコール使用障害の治療に有効である可能性があり、治療オプションが限られているこの状態に対する新たなアプローチを示唆しています。基礎メカニズムや性差、人種差に関する更なる研究が必要です。
<関連情報>
- https://news.vt.edu/articles/2024/01/research_fralinbiomed_GLPalcohol_0104.html
- https://www.nature.com/articles/s41598-023-48267-2
セマグルチドとティルゼパチドが肥満者のアルコール摂取を減少させる Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Fatima Quddos,Zachary Hubshman,Allison Tegge,Daniel Sane,Erin Marti,Anita S. Kablinger,Kirstin M. Gatchalian,Amber L. Kelly,Alexandra G. DiFeliceantonio & Warren K. Bickel
Scientific Reports Published:28 November 2023
DOI:https://doi.org/10.1038/s41598-023-48267-2
Abstract
Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. In the social media study, we report 8 major themes including effects of medications (30%); diabetes (21%); and Weight loss and obesity (19%). Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity.
